VSTM: רווח נקי למניה ב-12 החודשים האחרונים verastem.com
Verastem, Inc. is a recognized expert in developing inhibitors to combat genetically specific tumor mutations. The company's operations are accompanied by strict compliance with environmental regulations regarding the disposal of laboratory waste. The rolling annual earnings per share demonstrate the potential for fabless scaling via outsourced synthesis, and the -1.84 level reflects the current magnitude of this fundamental momentum.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_VSTM_-_Verastem-Inc._-_Earnings-per-share-for-the-last-four-quarters "Verastem Inc - רווח נקי למניה (EPS TTM) VSTM (תקופה 04.07.2022 - 11.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Verastem, Inc.
To filter risks, Verastem, Inc. (VSTM) must evaluate real capital efficiency via net income divided by the total number of shares over the last 12 months. By analyzing the EPS TTM annual metric, an investor can discern the business's ability to generate income against the backdrop of colossal clinical trial expenditures and fierce patent competition within the targeted oncology sector.
